Arti Subramanian, MD
Internal Medicine · Toledo, OHNPI 1194957431
Payments from drug & device makers
Across 237 payments — averaging $16.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$465
- AstraZeneca$425
- Boehringer Ingelheim$416
- AbbVie$397
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$340
- Novartis$242
- plus $2K from 21 others
What the payments were for
- Food & beverage$3,827100%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 39 | $465 |
| AstraZeneca | 16 | $425 |
| Boehringer Ingelheim | 25 | $416 |
| AbbVie(2 entities) | 25 | $397 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 19 | $340 |
| Novartis | 15 | $242 |
| Otsuka America Pharmaceutical, Inc. | 11 | $217 |
| GSK | 14 | $206 |
| Novo Nordisk | 13 | $189 |
| Lilly USA, LLC | 12 | $167 |
| Johnson & Johnson | 8 | $138 |
| Merck | 9 | $123 |
| Exact Sciences | 6 | $97 |
| Amgen | 5 | $79 |
| Amarin Pharma, Inc. | 4 | $77 |
| Bayer | 2 | $48 |
| Biohaven Pharmaceuticals, Inc. | 2 | $29 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $29 |
| Endogastric Solutions, Inc | 2 | $23 |
| Nevro Corp. | 1 | $23 |
| Mylan Specialty L.p. | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Abbott | 1 | $18 |
| Corcept Therapeutics | 1 | $14 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
| Alkermes, Inc. | 1 | $13 |
| GRT US Holding, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,842 in reported general payments places this provider in the 85th percentile of 4,428 internal medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 213 | $188,819 |
| EliquisApixaban | 129 | $110,396 |
| JardianceEmpagliflozin | 94 | $91,965 |
| JanuviaSitagliptin Phosphate | 36 | $49,099 |
| MyrbetriqMirabegron | 48 | $36,204 |
| XareltoRivaroxaban | 32 | $34,560 |
| OzempicSemaglutide | 33 | $34,412 |
| TrulicityDulaglutide | 35 | $33,434 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 36 | $25,263 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 26 | $20,970 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 44 | $20,794 |
| Breo ElliptaFluticasone/Vilanterol | 30 | $18,758 |
| Tresiba Flextouch U-100Insulin Degludec | 27 | $15,296 |
| Spiriva RespimatTiotropium Bromide | 19 | $10,952 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 337 | $10,000 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $206 | $240,025321 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat, Tradjenta | $416 | $132,755154 claims |
| PfizerEliquis | $465 | $110,396129 claims |
| MerckJanuvia | $123 | $49,09936 claims |
| Johnson & JohnsonXarelto | $138 | $34,56032 claims |
| Novo NordiskOzempic | $189 | $34,41233 claims |
| Lilly USA, LLCTrulicity | $167 | $33,43435 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $425 | $30,07656 claims |
| AbbVieLinzess | $397 | $9,64718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,428 internal medicine providers in Ohio.
Other internal medicine in Toledo
- Srini HejeebuToledo$410K
- Antoinette PragalosCincinnati$27.8M
- Steven FolkerthBeavercreek$9.1M
- Charles EgerCincinnati$8.7M
- Vadim KoshkinCleveland$6.1M
- Nizar DaboulMaumee$4.7M
- Douglas LoganCincinnati$4.7M
- Seref BornovaliLoveland$4.4M
- Yevgeniy BukhmanCanton$3.7M
- Leela VrishabhendraCincinnati$3.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.